Case and Research LetterSorafenib-induced Acute Generalized Exanthematous Pustulosis: An Increasing Association?Pustulosis exantemática generalizada aguda por sorafenib: ¿una relación en aumento?
Section snippets
Conflict of interests
The authors declare no conflict of interest.
References (10)
- et al.
Acute generalized exanthematous pustulosis (AGEP): a review and update
J Am Dermatol
(2015) - et al.
Toxicodermias graves: ¿existen las formas combinadas?
Actas Dermo-sifiliográficas
(2016) - et al.
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
J Am Dermatol
(2009) - et al.
Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer. Part II. Targeted therapies
J Am Dermatol
(2014) - et al.
Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern?
J Cutan Pathol
(2001)
There are more references available in the full text version of this article.
Cited by (0)
© 2017 AEDV. Published by Elsevier España, S.L.U. All rights reserved.